By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics, formerly known as Osmetech, today said that its US initial public offering has been priced at $6 per share, down from an earlier range of $8 to $10.

The company, which concurrent with the IPO changed its name to GenMark Diagnostics, is offering 4.6 million shares, and said that it expects trading to begin today on the Nasdaq Global Market under the symbol "GNMK."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.